FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

贝伐单抗 福尔菲里 医学 伊立替康 氟尿嘧啶 奥沙利铂 内科学 结直肠癌 胃肠病学 中性粒细胞减少症 肿瘤科 外科 临床终点 化疗 癌症 随机对照试验
作者
Chiara Cremolini,Fotios Loupakis,Carlotta Antoniotti,Cristiana Lupi,Elisa Sensi,Sara Lonardi,Silvia Mezi,Gianluca Tomasello,Monica Ronzoni,Alberto Zaniboni,Giuseppe Tonini,Chiara Carlomagno,Giacomo Allegrini,Silvana Chiara,Mauro D’Amico,Cristina Granetto,Marina Elena Cazzaniga,Luca Boni,Gabriella Fontanini,Alfredo Falcone
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:16 (13): 1306-1315 被引量:1123
标识
DOI:10.1016/s1470-2045(15)00122-9
摘要

Background In the TRIBE study, FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab significantly improved progression-free survival of patients with metastatic colorectal cancer compared with FOLFIRI (fluorouracil, leucovorin, and irinotecan) plus bevacizumab. In this updated analysis, we aimed to provide mature results for overall survival—a secondary endpoint—and report treatment efficacy in RAS and BRAF molecular subgroups. Methods TRIBE was an open-label, multicentre, phase 3 randomised study of patients (aged 18–70 years with Eastern Cooperative Oncology Group [ECOG] performance status of 2 or less and aged 71–75 years with an ECOG performance status of 0) with unresectable metastatic colorectal cancer who were recruited from 34 Italian oncology units. Patients were randomly assigned (1:1) via a web-based procedure to receive FOLFIRI plus bevacizumab or FOLFOXIRI plus bevacizumab. Bevacizumab was given as a 5 mg/kg intravenous dose. FOLFIRI consisted of a 180 mg/m2 intravenous infusion of irinotecan for 60 min followed by a 200 mg/m2 intravenous infusion of leucovorin for 120 min, a 400 mg/m2 intravenous bolus of fluorouracil, and a 2400 mg/m2 continuous infusion of fluorouracil for 46 h. FOLFOXIRI consisted of a 165 mg/m2 intravenous infusion of irinotecan for 60 min, followed by an 85 mg/m2 intravenous infusion of oxaliplatin given concurrently with 200 mg/m2 leucovorin for 120 min, followed by a 3200 mg/m2 continuous infusion of fluorouracil for 48 h. Tissue samples for RAS and BRAF mutational status analyses were centrally collected. In this updated analysis, we assessed the secondary endpoint of overall survival in the main cohort and treatment efficacy in RAS and BRAF molecular subgroups. All analyses were by intention to treat. TRIBE was concluded on Nov 30, 2014. The trial is registered with ClinicalTrials.gov, number NCT00719797. Findings Between July 17, 2008, and May 31, 2011, 508 patients were randomly assigned. At a median follow-up of 48·1 months (IQR 41·7–55·6), median overall survival was 29·8 months (95% CI 26·0–34·3) in the FOLFOXIRI plus bevacizumab group compared with 25·8 months (22·5–29·1) in the FOLFIRI plus bevacizumab group (hazard ratio [HR] 0·80, 95% CI 0·65–0·98; p=0·03). Median overall survival was 37·1 months (95% CI 29·7–42·7) in the RAS and BRAF wild-type subgroup compared with 25·6 months (22·4–28·6) in the RAS-mutation-positive subgroup (HR 1·49, 95% CI 1·11–1·99) and 13·4 months (8·2–24·1) in the BRAF-mutation-positive subgroup (HR 2·79, 95% CI 1·75–4·46; likelihood-ratio test p<0·0001). Treatment effect was not significantly different across molecular subgroups (pinteraction=0·52). Interpretation FOLFOXIRI plus bevacizumab is a feasible treatment option for those patients who meet the inclusion criteria of the present study, irrespective of baseline clinical characteristics and RAS or BRAF mutational status. Funding GONO (Gruppo Oncologico del Nord Ovest) Cooperative Group and ARCO Foundation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
FashionBoy的应助被务实的书芹采纳,获得10
2秒前
优美的未来完成签到,获得积分10
2秒前
guangtouqiang完成签到,获得积分20
2秒前
2秒前
聂的苏发布了新的文献求助10
2秒前
科研小能手的应助被嘻嘻嘻采纳,获得50
3秒前
123完成签到 ,获得积分10
3秒前
jing完成签到,获得积分20
3秒前
Jasper的应助被符聪采纳,获得10
3秒前
ZzHappyOvO完成签到,获得积分10
3秒前
冲冲冲发布了新的文献求助10
4秒前
吴冠超发布了新的文献求助10
4秒前
Mniwl发布了新的文献求助10
4秒前
桐桐的应助被靓丽芙蓉采纳,获得10
4秒前
5秒前
5秒前
WUHAO完成签到,获得积分10
5秒前
5秒前
阿涛发布了新的文献求助10
5秒前
大大纷完成签到,获得积分10
6秒前
zzzzz发布了新的文献求助10
6秒前
饭饭饭饭饭完成签到,获得积分10
6秒前
6秒前
陶醉的乞发布了新的文献求助10
7秒前
zsda完成签到,获得积分10
7秒前
7秒前
请不要叽叽喳喳完成签到 ,获得积分10
7秒前
lixiaotong完成签到,获得积分20
8秒前
8秒前
8秒前
9秒前
211107发布了新的文献求助10
9秒前
211107发布了新的文献求助10
9秒前
9秒前
9秒前
可爱的函函的应助被蓝染采纳,获得10
9秒前
可爱的函函的应助被小乌龟采纳,获得10
9秒前
10秒前
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175707
求助须知:如何正确求助?哪些是违规求助? 9567353
关于积分的说明 21792214
捐赠科研通 7770334
什么是DOI,文献DOI怎么找? 3431908
关于科研通互助平台的介绍 2556260
邀请新用户注册赠送积分活动 2477417